Close Menu

AACR

Investigators from the Friends of Cancer Research's tumor mutational burden harmonization project shared new data this week at AACR's virtual meeting.

Researchers argued that the field is ready for an expansion of adjuvant therapy trials informed by non-invasive, molecular measures of minimal residual disease.

At the AACR annual meeting, researchers shared detection rate data for multi-cancer screening tests from Grail and Thrive Earlier Detection.

A single-cell "atlas" of pathologically normal breast tissue was presented by an MD Anderson Cancer Center representative at the AACR's online annual meeting this week.

The project is collaborating with nine biopharma companies to combine more real-world clinical data with genomic data.

Inivata expects to publish initial data on the assay's detection abilities in lung cancer at the American Association for Cancer Research virtual meeting in July.

Research is accumulating for the improved performance of epigenetic signals over mutations, with multiple commercial efforts well underway.

Researchers are making improvements to viral-DNA detection methods and are exploring applications not just for screening but also disease monitoring.

In two trials in the neoadjuvant setting reported at SABCS, one showed improved rates of pathologic complete response with added immunotherapy, and the other showed no difference.

The TATTON study found a combination therapy could treat some EGFR-positive lung cancer patients who developed MET-based resistance, but the best way to gauge MET status isn't yet clear.

Pages